2-benzylphenyl-32-bromopropylether | 82827-57-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-benzylphenyl-32-bromopropylether
• 英文别名: (2-benzyl-phenyl)-(3-bromo-propyl)-ether；(2-Benzyl-phenyl)-(3-brom-propyl)-aether；2-(3-Brom-propyloxy)-1-benzyl-benzol；3-Brom-1-(2-benzyl-phenoxy)-propan；3-(2-Benzyl-phenoxy)-propylbromid；2-benzyl-1-(3-bromo-propoxy)-benzene；1-benzyl-2-(3-bromopropoxy)benzene
• CAS: 82827-57-4
• 化学式: C₁₆H₁₇BrO
• 分子量: 305.214
• InChiKey: VUJZIYKQBVVOQI-UHFFFAOYSA-N

物化性质

• 沸点：
  388.8±30.0 °C(Predicted)
• 密度：
  1.276±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-benzylphenyl-32-bromopropylether 、 2-甲基哌啶 在 1,4-二氧六环 作用下， 生成 1-[3-(2-benzyl-phenoxy)-propyl]-2-methyl-piperidine
  参考文献：
  名称：

  苄基酚的烷基氨基烷基醚。

  摘要：

  DOI：

  10.1021/ja01169a017
• 作为产物：
  描述：

  苯甲基苯酚 、 1,3-二溴丙烷 生成 2-benzylphenyl-32-bromopropylether
  参考文献：
  名称：

  Inhibitors of Akt (protein kinase B)

  摘要：

  本发明涉及化合物式(I): 作为AKT活性的抑制剂，适用于治疗易感肿瘤和病毒感染。

  公开号：

  US07414063B2

文献信息

• [EN] ISOQUINOLINE-5-SULFONIC ACID AMIDES AS INHIBITORS OF AKT (PROTEIN KINASE B)<br/>[FR] UTILISATION D'AMIDES D'ACIDE ISOQUINOLINE-5-SULFONIQUE COMME INHIBITEURS DE L'AKT (PROTEINE KINASE B)
  申请人：LILLY CO ELI

  公开号：WO2004094386A1

  公开（公告）日：2004-11-04

  The present invention relates to compounds Formula (I): as inhibitors of AKT activity, which are useful for the treatment of susceptible neoplasms and viral infections.

  本发明涉及化合物式(I)：作为AKT活性抑制剂，对易感肿瘤和病毒感染的治疗有用。
• Inhibitors of akt (protein kinase b)
  申请人：Al-Awar Salim Rima

  公开号：US20070043040A1

  公开（公告）日：2007-02-22

  The present invention relates to compounds Formula (I): as inhibitors of AKT activity, which are useful for the treatment of susceptible neoplasms and viral infections.

  本发明涉及化合物式(I)：作为AKT活性抑制剂，可用于治疗易感性肿瘤和病毒感染。
• Inhibitors of Akt (protein kinase B)
  申请人：Eli Lilly and Company

  公开号：US07414063B2

  公开（公告）日：2008-08-19

  The present invention relates to compounds Formula (I): as inhibitors of AKT activity, which are useful for the treatment of susceptible neoplasms and viral infections.

  本发明涉及化合物式(I): 作为AKT活性的抑制剂，适用于治疗易感肿瘤和病毒感染。
• Synthesis and antidepressant activity of substituted (.omega.-aminoalkoxy)benzene derivatives
  作者：Ryoji Kikumoto、Akihiro Tobe、Shinji Tonomura

  DOI：10.1021/jm00134a004

  日期：1981.2

  A series of substituted (omega-aminoalkoxy)benzene derivatives has been synthesized and screened for potential antidepressant activities. The effect of structural variation of these molecules has been systematically examined. Antidepressant activity was clearly displayed by 2-benzyl-1-[4-(methylamino)butoxy]benzene (7), 2-(2-hydroxybenzyl)-1-[4-(methylamino)butoxy]benzene (19), 1-[4-(methylamino)butoxy]-2-phenoxybenzene (29), and 1-[4-(methylamino)butoxy]-2-(phenylthio)benzene (31) in further pharmacological studies. These compounds did not possess the anticholinergic, antihistaminic, and muscle-relaxant side effects common to tricyclic antidepressants.
• Dopamine/Serotonin Receptor Ligands. 9. Oxygen-Containing Midsized Heterocyclic Ring Systems and Nonrigidized Analogues. A Step toward Dopamine D₅ Receptor Selectivity
  作者：Thomas W. Wittig、Michael Decker、Jochen Lehmann

  DOI：10.1021/jm049720x

  日期：2004.8.1

  Eleven-membered heterocycles (dibenz[g,j]-1-oxa-4-azacycloundecenes) and open-chain analogues were synthesized and investigated for affinities to human dopamine receptor subtypes. The moderately rigidized rings displayed nanomolar and sulmanomolar K-i values at D-1-like receptors with a significant D-1 to D-2 and a slight D-5 to D-6 selectivity. The open-chain analogues showed lower affinities but significant D-1 to D-2 selectivities. Compound 3 (K-i(D-5) = 0.57 nmol) showed antagonistic or inverse agonistic binding characteristics in a functional Ca assay.